Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aumolertinib”

57 trials

Showing 20 of 57 results

Testing effectiveness (Phase 2)UnknownNCT04905550
What this trial is testing

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Chongqing University Cancer Hospital 50
Not applicableUnknownNCT05663177
What this trial is testing

Almonertinib Plus Metronomic Oral Vinorelbine

Who this might be right for
EGFRNSCLCThird-generation TKI
Fujian Cancer Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05503888
What this trial is testing

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Who this might be right for
Relapsed or Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 160
Early research (Phase 1)Ended earlyNCT05048134
What this trial is testing

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd. 13
Large-scale testing (Phase 3)Looking for participantsNCT06043973
What this trial is testing

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Who this might be right for
Advanced Non-small Cell Lung Cancer
Qianfoshan Hospital 98
Testing effectiveness (Phase 2)UnknownNCT04922138
What this trial is testing

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Who this might be right for
Lung Cancer
Baohui Han 104
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Testing effectiveness (Phase 2)UnknownNCT04978753
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerBrain Metastases
Li-kun Chen 54
Testing effectiveness (Phase 2)UnknownNCT04646824
What this trial is testing

Almonertinib With Chemotherapy in mEGFR NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Tianjin Medical University Cancer Institute and Hospital 10
Not applicableUnknownNCT04944069
What this trial is testing

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Who this might be right for
NSCLCLeptomeningeal MetastasisEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT06300424
What this trial is testing

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Guangdong Provincial People's Hospital 32
Large-scale testing (Phase 3)Looking for participantsNCT04951635
What this trial is testing

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT04685070
What this trial is testing

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Stage III
Shanghai Pulmonary Hospital, Shanghai, China 56
Testing effectiveness (Phase 2)UnknownNCT04785729
What this trial is testing

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Who this might be right for
Safety
Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT04785742
What this trial is testing

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Who this might be right for
Safety of Almonertinib
Sun Yat-sen University 40
Testing effectiveness (Phase 2)UnknownNCT04952168
What this trial is testing

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Who this might be right for
NSCLC, Stage III
Yuan Chen 26
Not applicableUnknownNCT04778800
What this trial is testing

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Who this might be right for
NSCLCBrain MetastasesLeptomeningeal Metastasis
Henan Cancer Hospital 60
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation